NCT02581072View on ClinicalTrials.gov

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

April 30, 2016

Conditions
Acne Vulgaris
Interventions
DRUG

SB204 4%

Applied topically once

DRUG

SB204 8% or 12%

Applied once topically

DRUG

Vehicle

Applied topically once

Trial Locations (1)

53095

Spaulding Clinical Research, LLC, West Bend

All Listed Sponsors
collaborator

Spaulding Clinical Research LLC

OTHER

lead

Novan, Inc.

INDUSTRY

NCT02581072 - A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204 | Biotech Hunter | Biotech Hunter